No Data
shenzhen transsion holdings co., ltd.'s financial officer has been detained, serving for as long as 10 years.
①Xiao Yonghui has been the Chief Financial Officer of shenzhen transsion holdings co., ltd. since January 2014. The lawyer said that being placed under coercive measures means that the relevant parties may be subject to coercive measures by the supervisory authorities due to suspicion of illegal or criminal activities. ②Shenzhen Transsion Holdings Co., Ltd. has had outstanding performance in recent years, but it still faces challenges at present.
A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
Zhongcheng Insurance's equity has changed, and Guangzhou Financial Holdings has become the third largest shareholder. After 13 years in operation, there are still nearly 0.4 billion unrecovered losses on the books. Can it make a comeback in the electric v
① By the end of 2023, Zhongcheng Insurance, which has been in operation for 13 years, still has an unrecouped loss of nearly 0.4 billion yuan. ② In the first half of 2024, Zhongcheng Insurance achieved a premium of 0.842 billion yuan for electric vehicle insurance, a year-on-year increase of 49%. ③ In the first half of the year, after deducting the impact of income tax expenses, the net income of Zhongcheng Insurance was -0.3191 million yuan.
Is the GLP-1 pipeline progressing slowly? Gan & Lee Pharmaceuticals: GZR18 has the potential for superior weight reduction efficacy compared to multi-target drugs | Live coverage of the earnings conference.
At the earnings conference, the management of Gan & Lee Pharmaceuticals emphasized that the price regression of the company's insulin products in the follow-up volume procurement has driven the performance. In the face of doubts about the progress of GLP-1 pipeline research and competitiveness, Dou Kai, the General Manager of Gan & Lee Pharmaceuticals, stated that GZR18 injection has a weight loss effect that exceeds exenatide and dulaglutide, and has the potential to be superior to multi-target GLP-1RA drugs in weight loss efficacy.
Futu Morning News | The "arrow" of interest rate cuts is on the string! The hawkish voting committee suddenly released a dovish signal, and the market increased its bet on a 50 basis point interest rate cut; Tesla rose more than 4% against the market and
Fed Beige Book: More regional economic activity is stagnating, price pressures are stabilizing; Alleged to be facing antitrust investigation, Nvidia says it has not received a subpoena from the U.S. Department of Justice; C3.ai falls over 16% after hours, Q1 subscription revenue for fiscal year 2025 falls short of expectations.
Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.
①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.